Intra-Cellular Therapies Inc
NASDAQ:ITCI
Intra-Cellular Therapies Inc
Net Income (Common)
Intra-Cellular Therapies Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
I
|
Intra-Cellular Therapies Inc
NASDAQ:ITCI
|
Net Income (Common)
-$139.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-18%
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$40.6B
|
CAGR 3-Years
39%
|
CAGR 5-Years
23%
|
CAGR 10-Years
10%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$2.1B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-21%
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$5.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
See Also
What is Intra-Cellular Therapies Inc's Net Income (Common)?
Net Income (Common)
-139.7m
USD
Based on the financial report for Dec 31, 2023, Intra-Cellular Therapies Inc's Net Income (Common) amounts to -139.7m USD.
What is Intra-Cellular Therapies Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-18%
Over the last year, the Net Income (Common) growth was 46%. The average annual Net Income (Common) growth rates for Intra-Cellular Therapies Inc have been 15% over the past three years , 2% over the past five years , and -18% over the past ten years .